Neoplasm of mature T-cells or NK-cells
MONDO:0005169A group of neoplasms composed of T-lymphocytes with a mature (peripheral/post-thymic) immunophenotypic profile and/or NK-cells.
Also known as: mature T and NK neoplasms, mature T-cell and NK-cell neoplasm, mature T-cell neoplasm
2080 clinical trials for this condition and its sub-types, 4 tagged with Neoplasm of mature T-cells or NK-cells itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Neoplasm of mature T-cells or NK-cells
-
Mature T-cell and NK-cell non-Hodgkin lymphoma 150 trials · 240 incl. sub-types
8 sub-types
- Anaplastic large cell lymphoma 66 trials · 89 incl. sub-types Sub-types →
- Angioimmunoblastic T-cell lymphoma 58 trials
- T-cell large granular lymphocyte leukemia 18 trials
- T-cell prolymphocytic leukemia 17 trials
- Aggressive NK-cell leukemia 11 trials
- Breast implant-associated anaplastic large cell lymphoma 3 trials
- Hydroa vacciniforme-like lymphoma 3 trials
- Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood 2 trials
-
EBV-positive T-cell lymphoproliferative disorder of childhood 3 trials · 7 incl. sub-types
2 sub-types
Most studied deeper sub-types
-
New drug cocktail shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a combination of four drugs (romidepsin, CC-486, dexamethasone, and lenalidomide) in 26 adults with T-cell cancers that had returned or stopped responding to prior treatments. The main goal was to find a safe dose and check for side effects. While th…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC